What the Most Favored Nation (MFN) policy means for UK Pharma
October 20, 2026 |
By Jed Avissar and Manca Povsic
The UK has historically been a relatively low-priced drug market due to National Institute for Health and Care Excellence (NICE) assessments that link cost with effectiveness, NHS purchasing power, and the implementation of the Voluntary Scheme for Branded Medicines Pricing, Access and Growth framework. However, this is changing with the advent of MFN, as UK pricing and launch decisions are becoming more globally consequential.
The UK is included in the comparator baskets for the voluntary Generating Cost Reductions for US Medicaid (GENEROUS) model and the proposed mandatory Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding US Medicare Against Rising Drug Costs (GUARD) models, meaning that UK prices now directly influence the maximum US prices for the same therapies. As a result, UK teams must increasingly consider how local pricing, reimbursement and launch strategies could affect global pricing dynamics. In this blog, we explore the implications of MFN for UK teams and outline the actions UK market access, pricing and commercial leaders should be considering now.
What are the global consequences of UK pricing in the post-MFN world?
MFN is expected to narrow the price differential between the US and other developed markets. Evidence already shows consistent reductions in US list prices alongside increased UK list prices, as well as aligned US and UK prices at launch (see further details in our previous blog).1
Consequently, UK access can no longer be secured through traditional avenues, such as substantial discounting. Explicit net rebates now create an immediate US and global pricing risk. Instead, UK teams should prepare for options that maintain patient access without impacting net price. Since MFN was announced, the use of value-based and outcomes-based agreements has increased in the UK (see further details in our previous blog).1 Further opportunities for price protection exist in agreements not directly related to net price, for example, budget caps, fixed costs per patient and pay-for-performance arrangements.
Will increased focus on global launch sequencing put UK access at risk?
With UK prices now anchoring US prices, manufacturers may consider delaying or pausing the launch to protect US price exposure. Early signals show delayed or withdrawn UK launches in response to MFN pressures, particularly until ‘clarity on the MFN policies’ is received (see further details in our previous blog).1 We expect these trends to become increasingly common.
This creates a difficult balance; delaying a UK launch may reduce immediate global pricing exposure, but it restricts patient access and will likely attract scrutiny from patients, clinicians and policymakers. Opportunities to provide patient access outside conventional pricing channels, or via routes that afford higher prices, should be considered, such as early access programmes, private provider networks, self-pay channels and alternative funding routes. Accordingly, UK teams should engage early with payers to assess the feasibility, acceptability and strategic value of these approaches.
What should UK teams consider when assessing global launch planning?
Launch planning in the UK will now need to be based not just on achieving access at a certain discount or volume, but also on achieving access at a specific (higher) net price. If a lower price is projected, a delayed or reduced launch is likely; therefore, launch planning requires early UK alignment, particularly when developing the strategy and tactics for achieving a higher price. Plans should carefully consider the UK net price relative to MFN comparator markets, including the effect of potential discounts, expected NICE timelines, evidence requirements and comparator challenges.
What will UK teams need to build a case for a premium price?
Reducing reliance on discounts to achieve access will require a stronger basis for defending a premium price. The UK government’s commitment to higher spending on innovative medicines and increased NICE cost-effectiveness thresholds creates slightly more room for higher drug prices in the UK.2 Alongside this, it is imperative that UK teams build a compelling value narrative that clearly addresses key NICE expectations linked to premium pricing, including communication of high unmet need, evidence of durability of effect, differentiation into high-burden populations, and appropriate comparator selection. Comparative evidence generation will be increasingly important for pricing discussions, particularly in crowded therapy areas.
What does MFN ultimately mean for UK Pharma?
MFN has inextricably tied UK pricing, reimbursement and launch decisions to US pricing, and increased the global importance of achieving a premium price in this country. While the MFN policy introduces new constraints, it also increases the importance of proactive cross-functional planning and early internal alignment. Manufacturers that adapt early and anticipate the wider implications of UK pricing decisions will be best positioned to preserve value and secure patient access in this uncertain environment.
If your team is preparing for MFN, reviewing UK price exposure, launch sequencing or the evidence needed to support value, talk to our market access specialists.
References
- Amiculum. Navigating the new Most Favored Nation (MFN) reality: are pharma companies ready? Available at: https://www.amiculum.biz/insights/navigating-the-new-most-favored-nation-mfn-reality-are-pharma-companies-ready/?page=1 (accessed October 2026).
- Office of the United States Trade Representative. USTR Announces Initiation of Section 301 Investigation of Germany’s Persistent Underpayment for Innovative Pharmaceutical Products: 2026 Updated. Available at: https://ustr.gov/about/policy-offices/press-office/press-releases/2026/june/ustr-announces-initiation-section-301-investigation-germanys-persistent-underpayment-innovative (accessed October 2026).
This content was provided by Amiculum
Company Details
Latest Content from Amiculum
What the Most Favored Nation (MFN) policy means for UK Pharma
By Jed Avissar and Manca Povsic
Amiculum joins Bionow: supporting collaboration across the life sciences sector in the North of the UK
We’re delighted that Amiculum has become a member of Bionow, joining a collaborative community that plays an important role in bringing together life sciences organizations across the North of the…
PharmaQuest returns: EPA perspectives, through a rare disease lens
By Lottie Sequerra and Emily Morton-West
Amiculum reaffirms presence in Dundee with new office and continued academic partnership
Amiculum is pleased to announce the relocation of its Dundee team to a new, state-of-the-art facility at the Dundee Life Sciences Innovation Hub, an environment designed to accelerate scientific progress…
Winning in Pharma: the power of early strategic planning with patients
By Zoë van Helmond
Turn payer insights into impact with omnichannel engagement in market access
By Betty Charleshouse